ArticleProgress in rehabilitation medicine2026
Association of Exercise Tolerance with Survival in Patients with Hepatocellular Carcinoma Receiving Locoregional Therapy.
Article in Progress in rehabilitation medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Functional exercise capacity is impaired in patients with chronic diseases or malignancies. This study aimed to investigate the association between exercise tolerance and the prognosis of patients with hepatocellular carcinoma receiving locoregional therapy. Methods: This single-center prospective study enrolled 41 consecutive patients with hepatocellular carcinoma who had a Barthel index of 100 and received locoregional therapy. Baseline exercise tolerance, physical function, and body composition were measured. Factors associated with mortality were assessed using a Cox proportional hazards model. Recurrence-free and overall survival rates were evaluated using the Kaplan-Meier analysis and log-rank test. Results: Of the 41 patients, 16 were shown to have exercise intolerance through the 6-min walk test. None of the baseline laboratory data, physical function, body composition, or sarcopenia comorbidity showed significant differences between exercise-tolerant and exercise-intolerant patients. During a median follow-up period of 31 months, 8 patients died. The multivariate Cox proportional hazards model identified the baseline albumin-bilirubin score and exercise intolerance as independent predictors of mortality. Kaplan-Meier analyses showed that the overall, but not recurrence-free, survival rate was significantly lower in patients with exercise intolerance than in those with exercise tolerance. Conclusions: Exercise intolerance is associated with lower survival in patients with hepatocellular carcinoma receiving locoregional therapy. In particular, patients with albumin-bilirubin grade 2 and exercise intolerance may be at high risk of poor prognosis after locoregional therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.